Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vistin Pharma ASA ( (DE:VP4) ) has shared an update.
Vistin Pharma ASA is set to release its second quarter and year-to-date 2025 financial results on August 15, 2025, accompanied by a conference call for shareholders and interested parties. This announcement underscores the company’s commitment to transparency and engagement with stakeholders, potentially impacting its market position and investor relations.
More about Vistin Pharma ASA
Vistin Pharma is a Norwegian pharmaceutical company specializing in the production of Metformin Hydrochloride, an active pharmaceutical ingredient (API). As a dedicated European Metformin producer, Vistin Pharma supplies leading pharmaceutical companies and operates a manufacturing facility in Kragerø, Norway.
Average Trading Volume: 17,652
Current Market Cap: NOK1.09B
For a thorough assessment of VP4 stock, go to TipRanks’ Stock Analysis page.